From: Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis
 | n (%) |
---|---|
Pathogens | Â |
   Staphylococcus aureus | 131‡ (38.1) |
   Beta-hemolytic streptococci | 42 (12.2) |
   Viridans streptococci | 30 (8.7) |
   Enterobacteriaceae | 17 (4.9) |
   Streptococcus pneumoniae | 14 (4.1) |
   Pseudomonas aeruginosa | 10 (2.9) |
   Coagulase-negative staphylococci | 6 (1.7) |
   Mycobacteria spp. | 6 (1.7) |
   Other pathogens | 15 (4.4) |
   Polymicrobial infections | 64 (18.6) |
   No pathogen identified | 73 (21.2) |
Therapy †|  |
   Beta-lactams | 292 (84.9) |
Amoxicilline/Clavulanate | 129 (37.5) |
Penicilline | 54 (15.7) |
Flucloxacilline | 48 (14.0) |
Cephalosporines | 33 (9.6) |
Piperacilline/Tazobactam | 18 (5.2) |
Carbapenemes | 10 (2.9) |
   Non-beta-lactams |  |
Aminoglycosides (used in combination) | 10 (2.9) |
Fluoroquinolones | 8 (2.3) |
Antituberculosis drugs | 6 (1.7) |
Others | 28 (8.1) |